Voice Tech for Health
WE REGRET TO ANNOUNCE THE VOICE TECH FOR HEALTH 2020 SUMMIT HAS BEEN CANCELLED, DUE TO THE ESCALATION OF THE COVID-19 CORONAVIRUS OUTBREAK. IF YOU HAVE ANY QUERIES WITH REGARDS TO THIS EVENT, PLEASE GET IN TOUCH WITH US VIA THE CONTACT US PAGE.

Voice Tech for Health

May 13 - 15, 2020 | Boston, MA

Advancing The Next Generation of Patient Healthcare Through Voice Technology

Registration Agenda
Key Features
Exclusively Dedicated

This meeting is solely dedicated to catalyzing Voice Technology for Healthcare.

This summit has been built by the pioneers of the industry to ensure that the crucial opportunities and challenges facing this space are tackled head-on.

Diverse Audience

Indulge in high-quality discussions in this intimate setting with senior decision-makers from across healthcare, including Digital Health Companies, Pharma, Medical Devices, Healthcare Providers, Software Developers and more!

Patient-Centered Approach

Voice Technology has the potential to revolutionize patient health outcomes.

This summit is committed to improving the monitoring, prevention and treatment of patient populations.

Voice technology in healthcare is poised to change the way providers and patients make decisions, receive information, and interact with one another – from reducing administrative burden with natural language processing to placing smart assistants at the patient bedside.

Voice Tech for Health is an exciting opportunity to bring together thought leaders from different facets of the industry to ensure that voice technology continues to create value and improve experiences across the healthcare system.

Annie Hill, Innovation & Digital Health Accelerator, Boston Children's Hospital

The Voice Tech in health market is heating up – over the past year, we have seen more than $50M in raised startup investment, $30M in federal grant funding and $5M in pharmaceutical contracts dedicated to this field.

There is great promise in early diagnosis and intervention with voice biomarkers, and Voice Tech for Health is a way to get all key stakeholders in the same room to translate this work to patients faster

Jim Schwoebel, CEO, Neurolex

Voice Tech for Health will be showcasing some of the leading vocal biomarker technologies which are becoming an increasingly significant indicator used to influence, predict and explain health outcomes.Thanks to tremendous research and development progress in speech and voice in the past 10 years for consumer applications, the same voice technology is pushing the new frontier of healthcare.

Millie Liu, Founding Partner, First Star Ventures

Voice biomarkers have the potential to yield key insights into disease progression, drug efficacy, and the underlying biology of multiple disease areas. We’ve seen a marked increase in the number of pharmaceutical developers that are now collecting voice biomarker information as part of clinical studies. The amount of data available is growing rapidly. This conference is a highly focused opportunity to share ideas for how to interpret, and create value from, this data.

Antoun Nabhan, VP of Corporate Development, Pear Therapeutics

Vocal biomarkers will fundamentally change diagnostics and monitoring for many diseases. The technology is evolving with a rapid pace and the industry is expanding. The Voice Tech for Health Summit is the first conference that brings all major players to the table – I am very much looking forward to it.

Claudio Hasler, Co-Founder & CEO, Peak Profiling

Speaker Faculty

Jim Harper
Jim Harper
Co-Founder & COO
Sonde Health
Jim Harper
Co-Founder & COO
Sonde Health

Jim is the co-founder and chief operating officer of Sonde Health. He has over 25 years of experience harnessing innovative technologies to provide real-world solutions to important biological measurement problems that he draws on to lead Sonde’s technology platform development to harness as a vital sign and meaningful predictor of health using devices we already own.

Prior to Sonde, Jim was at MIT Lincoln Laboratory for 15 years where he led the development of new biotechnology and bioengineering capabilities and teams for a range of national security applications and government agencies. The projects he led rapidly transformed novel biotechnologies from laboratory proofs-of-concept to prototypes and deployed systems that have impacted national security and law-enforcement capabilities in biodefense, human DNA identification and characterization, and human health and performance monitoring.

Jim received a BS in Biochemistry from Furman University, a PhD in Biochemistry from the MIT Chemistry department, and was a postdoctoral research fellow at Harvard Medical School in the Center for Neurologic Diseases.

Jim Schwoebel
Jim Schwoebel
CEO
Neurolex
Jim Schwoebel
CEO
Neurolex

Currently, Jim is the founding CEO of NeuroLex Labs, a company that is making voice computing accessible to everyone. He is also the author of Introduction to Voice Computing in Python, a textbook that outlines a new definition for voice computing with 200+ starter scripts on GitHub to train the next-generation of voice computing experts. Previously, Jim was a founding Partner of NeuroLaunch and CyberLaunch which invested in and grew over 22 companies in the neuroscience, cybersecurity, and machine learning verticals. He holds a BS in biomedical engineering from Georgia Tech.

Tony Keating
Tony Keating
CEO
ResApp
Tony Keating
CEO
ResApp

Tony Keating is the founding CEO of ResApp Health, a digital health company developing smartphone applications for the diagnosis and management of respiratory disease.

Prior to joining ResApp, Tony was Director, Commercial Engagement at UniQuest Pty Ltd, one of the global leaders in commercialisation of university technology. While at UniQuest, Tony held roles as interim CEO and Non-Executive Director for a number of privately-held, venture-capital funded start-up companies. Earlier in his career, Tony held business development and engineering management roles at Exa Corporation, makers of engineering simulation and visualization software.

Tony holds 3 engineering degrees (BEng, MEng and PhD), all from The University of Queensland. He also has an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.

Rupal Patel
Rupal Patel
CEO & Founder
Vocal iD
Rupal Patel
CEO & Founder
Vocal iD

Rupal is the Founder and CEO of VocaliD, a voice technology company that provides AI-generated voices with personality. VocaliD’s award-winning technology leverages the latest advances in machine learning, signal processing and voice analytics along with the company’s crowdsourced Voicebank to create inclusive, diverse and brand aligned voices for organizations and individuals with special needs. Rupal began her career as a speech clinician where she became fascinated with the potential of using speech technologies for assistive communication which then led to a doctorate in speech science. Her interdisciplinary research applies empirical evidence about speech motor control to develop novel communication technologies. She is currently on leave from Northeastern University where she is a tenured professor in the Khoury College of Computer Sciences and the Department of Communication Sciences and Disorders. Named one of The Top 11 Visionaries in Voice 2019 by Voicebot.ai and Fast Company’s 100 Most Creative People in Business, Rupal has been featured on TED, NPR, and in major international news and technology publications.

Guillermo Cecchi
Guillermo Cecchi
Principal Research Staff Member
IBM
Guillermo Cecchi
Principal Research Staff Member
IBM

Dr. Cecchi is a Principal Research Staff Member of IBM Research. Dr. Cecchi has been interested in diverse aspects of theoretical biology, including Brownian transport, molecular computation, spike reliability in neurons, song production and representation in songbirds, statistics of natural images and visual perception, statistics of natural language, and brain imaging.In recent years, he has developed a computational linguistics approach to quantify psychiatric conditions from short speech samples, applying it successfully to conditions as diverse as schizophrenia, mania, prodromal psychosis, and drug and alcohol intake, and directs the Computational Psychiatry and Neuroimaging research group in the Health Care and Life Sciences department of the T.J. Watson IBM Laboratory.

David Liu
David Liu
CEO
Sonde Health
David Liu
CEO
Sonde Health

David Liu is the chief executive officer of Sonde Health. He is a business leader who has successfully launched, led and scaled companies and products in the consumer internet, education and healthcare technology industries.

David most recently served as president and chief operating officer at Quartet, helping to scale it into a leading healthcare technology company that connects primary care physicians with mental health providers to improve overall health outcomes for patients. Before Quartet, David was president and chief operating officer at Knewton, where – from an early stage – he helped to build a leading global education technology company that uses machine learning to create personalized digital textbooks that improve student learning outcomes. David began his technology career with a decade at AOL Inc., where he was senior vice president and general manager leading multiple product areas, including instant messaging, and launched the original AOL.com portal as an internal start-up. David began his career as an automotive engineer for General Motors.

David recently served as an entrepreneur-in-residence at Weill Cornell Medicine (WCM), where he evaluated developing technologies in therapeutics, diagnostics, devices and digital healthcare. He is an advisor to and investor in several technology start-ups.

David received a BS in Industrial Engineering from Purdue University and an MBA from Columbia Business School.

Liam Kaufman
Liam Kaufman
CEO
Winterlight Labs
Liam Kaufman
CEO
Winterlight Labs
Claudio Hasler
Claudio Hasler
Co-Founder & CEO
Peak Profiling
Claudio Hasler
Co-Founder & CEO
Peak Profiling

Claudio Hasler is Co-Founder and CEO of PeakProfiling – a pioneer in speech sound analysis. Based on more than 20 years of research, the company is able to detect mental and physical disorders from the sound of the human voice. Previously, Mr. Hasler was leading the Business Intelligence and Analytics departments as well as all digital activities of an OTC player. Moreover, he has been working for Google in various roles, e.g. as Industry Manager.

Annie Hill
Annie Hill
Strategy & Business Development Associate, Innovation & Digital Health Accelerator
Boston Children's Hospital
Annie Hill
Strategy & Business Development Associate, Innovation & Digital Health Accelerator
Boston Children's Hospital

Annie Hill is a Strategy and Business Development Associate for the Innovation and Digital Health Accelerator (IDHA). She manages IDHA portfolio projects that focus on improving the patient and provider experience through the use of digital innovation  at Boston Children’s Hospital. As part of this portfolio, Annie manages the implementation of two of IDHA’s largest partnerships with voice technology companies in the hospital. Her role also includes market research, strategic development, and business analysis to ensure that project implementation aligns with hospital strategy.

Antoun Nabhan
Antoun Nabhan
VP, Corporate Development
Pear Therapeutics
Antoun Nabhan
VP, Corporate Development
Pear Therapeutics

Antoun has experience leading the corporate development and/or finance functions at several successful biotechnology and medical device companies.

Antoun Nabhan was Vice President of Corporate Development at Raptor Pharmaceuticals, Inc., where he oversaw licensing and strategic transactions prior to Raptor’s acquisition by Horizon Pharmaceutics. He led Raptor’s acquisition of Tripex, Inc., adding to the company’s portfolio a product now approved for treatment of bacterial infections of the lung and marketed as Quinsair(R). Prior to joining Raptor, he served at Capnia, Inc. as VP of Corporate Development, where he managed their November 2014 IPO. Before Capnia, Antoun was a Senior Director in Onyx Pharmaceuticals’ Corporate Development and Strategy group. While there, he had responsibility for for multiple inbound and outbound transactions, including the acquisition of Proteolix, Inc. This added to Onyx’s portfolio a product now approved for treatment of multiple myeloma and marketed as Kyprolis(r) (carfilzomib). Prior to Onyx, he was a founding executive of three private biotechnology companies, Presidio Pharmaceuticals, Inc. Incellico, Inc., and Convivia. From 2001-2006 he served in positions of increasing responsibility with Sagamore Bioventures, where he led investments in private and public biotechnology companies. Antoun received a B.A. from the University of Chicago and a J.D. from Harvard Law School. He has served on the Board of Directors of BayBio, Presidio Pharmaceuticals, and Cellerant, Inc., as well as the Mayor’s Biotech Advisory Council under San Francisco Mayor Gavin Newsom.

Joel Schwartz
Joel Schwartz
Quantitative Medicine & Clinical Tech Group
Biogen
Joel Schwartz
Quantitative Medicine & Clinical Tech Group
Biogen

Joel is an innovative and creative scientist who leverages experience in neurobiology, physics, instrumentation and statistics to generate and analyze large data sets.  Currently, he is a Sr Manager at Biogen in the Quantitative Medicine and Clinical Technologies group. Joel started his career at Vanderbilt University where he obtained a PhD in the center for molecular neuroscience under Dr. Louis J DeFelice studying neurotransmitter transporter.  After graduate school, Joel was hired as the managing director of imaging at the Stowers Institute for medical research. He was responsible for the development of light microscopy-based methodologies and image analysis. Joel left this position to purse work with Dr. Michael Ehlers at Duke University studying key molecular components for synaptic plasticity. He served as a technology lab lead within the Neuroscience Research Unit at Pfizer to build a strong technology base for advanced experimentation and informatics support. Joel served as a translator between the biologists, statisticians, physicists, and computer infrastructure professionals.

Stephen Penney
Stephen Penney
Voice, Cloud & App Developer
Brigham & Women's Hospital
Stephen Penney
Voice, Cloud & App Developer
Brigham & Women's Hospital
Henry O’Connell
Henry O’Connell
CEO & Founder
Canary Speech
Henry O’Connell
CEO & Founder
Canary Speech

Henry O’Connell has over 20 years of executive and C-level experience. Following graduate school,O’Connell began his career at the National Institutes of Health in a neurological disease group and continued on to a successful business career specializing in turnaround situations in the tech industry. He has served on several boards in both the private and public sector. O’Connell’s vast experience spans globally, as he has managed companies in North America, Europe, and Asia.

Millie Liu
Millie Liu
Founding Partner
First Star Ventures
Millie Liu
Founding Partner
First Star Ventures

Millie Liu has focused her career on helping entrepreneurs with deep technology turn their ideas into great businesses with global reach.
She was previously at APT, an enterprise data analytics startup acquired by Mastercard for $600m where she helped Fortune 50 clients such as Walmart and P&G make better strategic decisions leveraging data. She was also the co-founder of an MIT startup working on unsupervised event detection, which later pivoted and became Infervision, an AI precision healthcare platform backed by Sequoia China. Millie is on the advisory board of MIT CSAIL (Computer Science and Artificial Intelligence Lab). She holds a Master of Finance degree from MITand B.S. in Mathematics from the University of Toronto.

Daniel Jones
Daniel Jones
Co-Founder & CEO
Aural Analytics
Daniel Jones
Co-Founder & CEO
Aural Analytics
Maher Khaled
Maher Khaled
Business Development Manager
ResApp
Maher Khaled
Business Development Manager
ResApp
James Wyman
James Wyman
CFO & Co-Founder
Pillo Health
James Wyman
CFO & Co-Founder
Pillo Health

James is the Co-Founder & CFO of Pillo Health – an in-home digital care management company. He is responsible for global finance & operations.

Prior to Pillo Health, James spent 7 years in the financial and technology industries. He began his career at Morgan Stanley, working for the firm in both London and New York. In 2011 he was part of the founding team of Morgan Stanley’s “Private Capital Markets” group, which specialized in raising equity and equity-linked capital for private companies in the technology, consumer retail, and healthcare services sectors.

James previously served as VP Partnerships and a board member of InSITE, a competitive fellowship program focused on strengthening the entrepreneurial ecosystem in New York City.

He completed his MBA at Columbia Business School, where he focused on Entrepreneurship & Venture Capital Investing, and has a Bachelor’s Degree in Economics from Brown University. He is also a CFA Charter holder having passed all three exams on his first attempt.

Tal Wenderow
Tal Wenderow
CEO
Vocalis Health
Tal Wenderow
CEO
Vocalis Health
Jim Gemmell
Jim Gemmell
CTO
Aural Analytics
Jim Gemmell
CTO
Aural Analytics
Halim Abbas
Halim Abbas
Chief AI Officer
Cognoa
Halim Abbas
Chief AI Officer
Cognoa

Halim is a high tech innovator who spearheaded world-class data science projects at game changing techs like eBay and Teradata. Formally educated in Machine Learning, his professional expertise span Information Retrieval, Natural Language Processing, and Big Data. Halim has a proven track record of applying state of the art data science techniques across industry verticals such as eCommerce, web & mobile services, airline, BioPharma, and the medical technology industry. He currently leads the AI department at Cognoa, a data driven pediatric behavioral healthcare startup in Palo Alto.

Wolf Shlagman
Wolf Shlagman
Founder & CEO
Care Angel
Wolf Shlagman
Founder & CEO
Care Angel

Wolf Shlagman, a lifelong creative technologist, healthcare futurist and cognitive science evangelist, is currently CEO/Founder of Care Angel. As a serial entrepreneur, Wolf previously founded Consult a Doctor, which was acquired by Teladoc, INC (NYSE:TDOC), a Kleiner, Perkins portfolio company in 2013.

Wolf is an innovator that has been shaping and transforming the telehealth space since the earlier days of digital health, nearly 20 years ago. He is a technology and business leader with executive level strategic, technical and partnership development experience. He is recognized as beings a hands on leader  who is driven by passion in the pursuit of building impactful, enterprise platforms and consumer solutions targeted to help alleviate the most pressing challenges affective the entire health ecosystem.

Wolf considers himself a professional tinkerer, an AI addict and a behavioral economics fanatic with a demonstrated history of success.

Taha Jangda
Taha Jangda
General Partner
HealthX Ventures
Taha Jangda
General Partner
HealthX Ventures

Taha started his journey at the Texas Medical Center (TMC), the world’s largest medical center. During his time with TMC, he took part in the creation of the TMC Innovation Institute which is comprised of a healthcare and life science startup accelerator/incubator, Johnson & Johnson Innovation Center for Device Innovation and JLABS, and AT&T Connected Health Foundry.

Having seen firsthand how a lack of integration hinders patient care, Taha followed his entrepreneurial spirit and later joined Redox as the Director of Strategic Partnerships to help digital solutions get into the hands of care providers faster. Beyond tackling today’s most challenging healthcare issues and advising innovation communities across the country, Taha spends his free time reading books on leadership development and staying true to his Texas roots – BBQ and football.

David Leitman
David Leitman
Scientific Program Officer
National Institute of Mental Health
David Leitman
Scientific Program Officer
National Institute of Mental Health

David is a scientific program officer and chief of the Social Neuroscience and Communication in Adult Psychopathology Program at the National Institute of Mental Health (NIMH).  Dr. Leitman’s research expertise is in social communication, auditory and language neuroscience, Schizophrenia, and multimodal neuroimaging. Before joining NIMH, David was a research scientist and assistant professor at the Centre de Recherche en Neurosciences de Lyon  (CRNL-INSERM), and the University of Pennsylvania He holds a Ph.D. in Cognitive Neuroscience.

Reza Hosseini
Reza Hosseini
Chief Medical Officer
Neurolex
Reza Hosseini
Chief Medical Officer
Neurolex

Reza’s passion lies at the intersection of neuropsychiatry, technology, and education. He is most interested in exploring digital biomarkers in neuropsychiatry. In addition to his clinical practice as a cognitive and memory focused neuropsychiatrist, he is Chief Medical Officer at NeuroLex Laboratories where he leads a robust research pipeline and servicing industry and academic customers for their voice collection computing needs. He holds a BS in electrical and computer engineering from Rensselaer Polytechnic Institute, a MSE in biomedical and electrical engineering from Johns Hopkins University, and a MD from University of Massachusetts Medical School. He completed the University of Washington’s psychiatry residency and their neurology movement disorders fellowship to focus on neurodegenerative disease. Find more information about Reza at BrainMindedMD.com

Workshops - May 13th

  • Workshop 1: Voice Tech For Health 101
  • Workshop 2: Voice Tech Commercialization Deep Dive
Workshop 1: Voice Tech For Health 101
Voice Tech For Health 101

Voice technology is the next wave of digital health innovation and the use of voice is beginning its implementation across healthcare. With the field being so broad, there is a need for those involved to understand the full cohort.

Led by pioneers of the industry, this workshop will provide those new to the field the opportunity to be fully in the know and ready for the conference ahead.

Workshop Leaders: 

Jim Harper, Co-Founder & COO, Sonde Health

David Leitman, Program Chief, National Institute of Mental Health

9:00 am
Presentation: What Role can Voice Play in Healthcare and Drug Development?
9:30 am
Breakout Discussions

Splitting into smaller working groups, each group will discuss their current views on voice tech for health as a concept and their views on the different facets of the industry.

  • Are we comfortable with how the use of voice is being pursued in health?
  • Generally speaking, how do payers and regulatory authorities view the use of voice in digital health?
  • What lessons can we draw on from working with other related industries?
  • How are patient’s responding to voice tech as a health solution?
  • What remaining questions do we have about voice in health?
10:30 am
Refreshment Break
11:00 am
Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.

Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:

Leave this workshop with:

  • Fundamental questions answered around how voice can aid healthcare
  • A deeper understanding of the current payer and provider perspectives on the use of voice in health and how these are looking to be advanced
  • Up-to-date information on the different ways key stakeholders are involved in the industry
  • A fundamental understanding of the current privacy and security challenges
  • A stronger appreciation of the crucial questions facing the industry that will be tackled during the rest of the Summit.
12:00 pm
End of Workshop 1
Workshop 2: Voice Tech Commercialization Deep Dive
Voice Tech Commercialization Deep Dive - WORKSHOP LEADERS

For those looking to implement voice technology across healthcare, having an advanced understanding of the business models in place is valuable. However as this space is early in its lifecycle, key questions remain regarding routes to market and regulatory approval. Led by established leaders in this space, this workshop will inform and educate the industry to be better equipped for when they want to enter the market. 

Workshop Leaders: 

Jim Schwoebel, CEO, Neurolex

Tony Keating, CEO, ResApp

1:00 pm
Presentation: How Can We Commercialize Voice Technology?
1:30 pm
Breakout Discussions

Splitting into smaller working groups, each group will discuss the following:

  • There is currently no definitive insurance process yet for voice techs.
  • Should we follow the route those have started to take or is there a better route to secure reimbursement?
  • Over 80% of hospitals use the FHIRE policy, should voice tech be using this policy and if so, what standard does voice tech need to be up to, to gain FHIRE approval?
  • Beyond the US, which policies should voice tech be working towards in Europe?
  • Pharma, med techs and insurers – what are the benefits and who should voice techs be partnering with?
  • Doctors or pharma companies – who should voice tech be selling to?
2:30 pm
Refreshment Break
3:00 pm
Feedback Discussions

Representative(s) from each group share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised during this collaborative discussion.

Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:

Leave this workshop with:

  • An overview of the commercialisation opportunities currently available for voice technology in healthcare.
  • An informed understanding of the reimbursement models currently available and the next steps the industry should take to encourage mainstream reimbursement for voice technology.
  • Further knowledge into the regulatory policies currently setting the standards for voice technology and the level of standards needed to gain regulatory approval.
  • A better understanding of the business models available and the benefits each route to market can have for this industry.
  • A stronger patient-centered perspective; walk away with insights into how voice technology can be most valuable to patients using their products.
4:00 pm
End of Workshop 2

2020 Agenda

  • Thursday, May 14th 2020
  • Friday, May 15th 2020
Thursday, May 14th 2020
8:00 am
Registration, Breakfast & Networking

How Will Voice Tech Improve the Lives of Patients?

9:00 am
Chair’s Opening Remarks

Jim Harper, Co-Founder & COO, Sonde Health

9:10 am
Keynote Presentation - Voice Technology for Healthcare: Where Are We Currently and Where Do We Need To Go?

Tony Keating, CEO, ResApp

9:35 am
Interactive Panel & Open Q&A - How Can Voice Technology Improve the Lives of Patients?

Tony Keating, CEO, ResApp

Rupal Patel, CEO & Founder, Vocal iD

Annie Hill, Strategy & Business Development Associate, Innovation & Digital Health Accelerator, Boston Children’s Hospital

James Wyman, CFO & Co-Founder, Pillo Health

10:00 am
Morning Refreshments & Networking

Monitoring, Preventing and Improving Patient Conditions

11:00 am
Presentation - IBM’s development of Vocal Biomarkers as a Tool to Manage and Prevent Patient Conditions

Guillermo Cecchi, Principal Research Staff Member, IBM

11:25 am
Presentation - Improving Pediatric Patient Care Using Voice Technology at Boston Children's Hospital

Annie Hill, Strategy & Business Development Associate, Innovation & Digital Health Accelerator, Boston Children’s Hospital

12:00 pm
Lunch & Networking
1:30 pm
Presentation - Harnessing Voice as a Vital Sign - Sonde Health

David Liu, CEO, Sonde Health

1:55 pm
Presentation - Detecting & Monitoring Cognitive Diseases using Vocal Biomarkers

Liam Kaufman, CEO, Winterlight Labs

2:20 pm
Interactive Panel and Open Q&A - How can we Improve Voice Technology to Better Manage Patient’s Health?

Guillermo Cecchi, Principal Research Staff Member, IBM

Claudio Hasler, Co-Founder & CEO, Peak Profiling

Joel Schwartz, Quantitative Medicine & Clinical Tech Group, Biogen

Antoun Nabhan, VP, Corporate Development, Pear Therapeutics

Halim Abbas, Chief AI Officer, Cognoa

 

 

2:45 pm
Afternoon Refreshments & Networking

Accessibility & Personalization

3:30 pm
Presentation - Adopting Voice to Improve Accessibility in Hospitals and for Patients with Rheumatoid Arthritis

Stephen Penney, Voice, Cloud & App Developer, Brigham & Women’s Hospital

3:55 pm
Presentation - Analysing the CNS: Canary Speech’s Unique Approach in Voice Technology

Henry O’Connell, CEO & Founder, Canary Speech

4:20 pm
Interactive Panel and Open Q&A - Are We in Danger of Making Voice Technology Inaccessible for Patients?

Jim Schwoebel, CEO, Neurolex

Liam Kaufman, CEO, Winterlight Labs

James Wyman, CFO & Co-Founder, Pillo Health

Wolf Shlagman, Founder & CEO, Care Angel

5:05 pm
Close of Day 1
Download Agenda
Friday, May 15th 2020
8:00 am
Breakfast & Networking
9:00 am
Chair’s Opening Remarks

Jim Schwoebel, CEO, Neurolex

Building Routes to Market for Voice Tech

9:10 am
Keynote Presentation - Aural Analytics Share Their Journey To Commercialization

Daniel Jones, Co-Founder & CEO, Aural Analytics

9:35 am
Presentation - Conducting Clinical Trials in Voice Technology

Claudio Hasler, Co-Founder & CEO, Peak Profiling

10:00 am
Interactive Panel and Open Q&A - Commercializing Voice Tech: Building an Ecosystem for Success

Maher Khaled, Business Development Manager, ResApp

Daniel Jones, CEO & Co-Founder, Aural Analytics

Millie Liu, Founding Partner, First Star Ventures

Taha Jangda, General Partner, HealthX Ventures

10:45 am
Morning Refreshments & Networking
11:30 am
Fireside Chat - How Vocalis Health Was Born and Their Journey Ahead

Tal Wenderow, CEO, Vocalis Health

Antoun Nabhan, VP, Corporate Development, Pear Therapeutics

11:55 am
Presentation - Vocal identity: Design, Implementation and Why it Matters For Individuals and Organizations

Rupal Patel, CEO & Founder, Vocal iD

Data Privacy – What We Do & Don’t Know

12:20 pm
Interactive Panel and Open Q&A - Data Privacy & Security - What’s Keeping You Up At Night?

Tal Wenderow, CEO, Vocalis Health

Jim Gemmell, CTO, Aural Analytics

Erum Azeez, CEO, Soundmind

 

1:00 pm
Lunch & Networking

Integrating Voice into the Next Generation of Healthcare

2:15 pm
Interactive Panel and Open Q&A - What Should the Voice Technology Ecosystem Look Like Going Forward?

David Leitman, Program Chief, National Institute of Mental Health

Millie Liu, Founding Partner, First Star Ventures

Taha Jangda, General Partner, HealthX Ventures

2:50 pm
Chair’s Summary

Jim Schwoebel, CEO, Neurolex

3:00 pm
Close of Voice Tech for Health Summit 2020
Download Agenda

Partner with us

Our attendees tell us that one of the main reasons they attend our summits is to advance partnership discussions and forge new business relationships.  To facilitate this (and help us to fund the event) we have a limited number of partnership opportunities. This means that our partners can be confident they can have the meaningful conversations they seek – and our attendees know that the composition of the audience is just right.

We invite you to get in touch for a no-obligation conversation. We will share our audience data with you and help you determine whether Voice Tech for Health is the right fit for you.

Contact Us +
Partner with us

Register for the Event

For pricing and booking options please click the button to go to the registration page.

Registration